Portal de Periódicos da CAPES

A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries

2020; Elsevier BV; Volume: 135; Linguagem: Inglês

10.1016/j.ejca.2020.05.015

1879-0852

Yazid Belkacémi, N. Grellier, Sahar Ghith, Kamel Debbi, Gabriele Coraggio, Adda Bounedjar, R Samlali, Pelagia G. Tsoutsou, M. Ozsahin, Marie-Pierre Chauvet, Sedat Türkan, Hamouda Boussen, Abraham Kuten, Dušanka Tešanović, Hassan Errihani, F Benna, Kamel Bouzid, Ahmed Idbaïh, Karima Mokhtari, Lazar Popović, Jean-Philippe Spano, Jean-Pierre Lotz, Aziz Cherif, Hahn To, Vladimir Kovčin, Oliver Arsovski, S. Beslija, Radan Džodić, Ivan Marković, S. Vasović, Liljana Stamatovic, Davorin Radosavljević, Siniša Radulović, Damir Vrbanec, S. Sahraoui, Nino Vasev, Igor Stojkovski, Milan Risteski, Salvador Villà Freixa, Marco Krengli, Nina Radošević, Giorgio Mustacchi, Mladen Filipovic, Khaldoun Kerrou, Alphonse G. Taghian, Vladimir Todorović, Fady Geara, Joseph Gligorov,

Economic and Financial Impacts of Cancer

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer.Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low- and middle-income countries (LMICs). In this review, we aimed to summarize these international guidelines in accordance with cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumour criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints.